Torrent Pharmaceuticals shares experienced a surge in trading volume, rising 0.64% to Rs 3,554.20. The stock is a constituent of the NIFTY NEXT 50 index.
On September 24, 2025, Torrent Pharmaceuticals issued an intimation regarding the issue of commercial papers. Earlier, on September 23, the company announced updates on acquisition under Regulation 30 (LODR). On September 18, the company announced the redemption of commercial papers issued under ISIN: INE685A14146.
Here's a look at the company's recent financial performance:
| Heading | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 2,859.00 Crore | Rs 2,889.00 Crore | Rs 2,809.00 Crore | Rs 2,959.00 Crore | Rs 3,178.00 Crore |
| Net Profit | Rs 457.00 Crore | Rs 453.00 Crore | Rs 503.00 Crore | Rs 498.00 Crore | Rs 548.00 Crore |
| EPS | 13.51 | 13.37 | 14.88 | 14.71 | 16.19 |
The revenue for the quarter ending June 2025 was Rs 3,178.00 Crore, which is higher compared to previous quarters. Similarly, the net profit for June 2025 stood at Rs 548.00 Crore, up from Rs 457.00 Crore in June 2024.
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 8,004.57 Crore | Rs 8,508.04 Crore | Rs 9,620.15 Crore | Rs 10,727.84 Crore | Rs 11,516.09 Crore |
| Net Profit | Rs 1,251.88 Crore | Rs 777.18 Crore | Rs 1,245.23 Crore | Rs 1,656.38 Crore | Rs 1,911.25 Crore |
| EPS | 73.98 | 45.93 | 36.79 | 48.94 | 56.47 |
| BVPS | 344.90 | 351.75 | 183.13 | 202.57 | 224.27 |
| ROE | 21.44 | 13.05 | 20.09 | 24.15 | 25.17 |
| Debt to Equity | 0.83 | 0.67 | 0.85 | 0.57 | 0.40 |
The annual financial performance shows consistent growth. Revenue increased from Rs 8,004.57 Crore in 2021 to Rs 11,516.09 Crore in 2025. Similarly, net profit rose from Rs 1,251.88 Crore in 2021 to Rs 1,911.25 Crore in 2025. The company’s debt-to-equity ratio has also decreased from 0.83 in 2021 to 0.40 in 2025.
Consolidated Income Statement (Yearly)
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Sales | 11,516 | 10,727 | 9,620 | 8,508 | 8,004 |
| Other Income | 23 | 57 | 45 | 196 | 56 |
| Total Income | 11,539 | 10,785 | 9,665 | 8,704 | 8,061 |
| Total Expenditure | 8,614 | 8,080 | 7,484 | 7,223 | 6,182 |
| EBIT | 2,925 | 2,705 | 2,180 | 1,480 | 1,879 |
| Interest | 252 | 353 | 333 | 255 | 352 |
| Tax | 761 | 695 | 601 | 448 | 274 |
| Net Profit | 1,911 | 1,656 | 1,245 | 777 | 1,251 |
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | |
|---|---|---|---|---|---|
| Sales | 3,178 | 2,959 | 2,809 | 2,889 | 2,859 |
| Other Income | -37 | -18 | 33 | -16 | 24 |
| Total Income | 3,141 | 2,941 | 2,842 | 2,873 | 2,883 |
| Total Expenditure | 2,347 | 2,220 | 2,094 | 2,148 | 2,152 |
| EBIT | 794 | 721 | 748 | 725 | 731 |
| Interest | 56 | 56 | 57 | 64 | 75 |
| Tax | 190 | 167 | 188 | 208 | 199 |
| Net Profit | 548 | 498 | 503 | 453 | 457 |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Operating Activities | 2,585 | 3,266 | 2,368 | 1,802 | 2,010 |
| Investing Activities | -540 | -167 | -2,415 | -196 | -449 |
| Financing Activities | -2,297 | -2,779 | 77 | -1,781 | -1,656 |
| Others | -8 | 8 | 79 | 0 | 5 |
| Net Cash Flow | -261 | 326 | 110 | -174 | -89 |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Share Capital | 169 | 169 | 169 | 84 | 84 |
| Reserves & Surplus | 7,421 | 6,686 | 6,028 | 5,868 | 5,752 |
| Current Liabilities | 4,717 | 5,425 | 5,447 | 4,415 | 4,891 |
| Other Liabilities | 2,681 | 2,779 | 3,366 | 2,731 | 3,345 |
| Total Liabilities | 14,989 | 15,060 | 15,011 | 13,099 | 14,074 |
| Fixed Assets | 8,086 | 8,160 | 8,549 | 6,792 | 7,612 |
| Current Assets | 5,622 | 5,611 | 5,329 | 5,294 | 5,523 |
| Other Assets | 1,281 | 1,288 | 1,133 | 1,012 | 938 |
| Total Assets | 14,989 | 15,060 | 15,011 | 13,099 | 14,074 |
| Contingent Liabilities | 465 | 575 | 619 | 505 | 324 |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 56.47 | 48.94 | 36.79 | 45.93 | 73.98 |
| Diluted Eps (Rs.) | 56.47 | 48.94 | 36.79 | 45.93 | 73.98 |
| Book Value [Excl. Reval Reserve]/Share (Rs.) | 224.27 | 202.57 | 183.13 | 351.75 | 344.90 |
| Dividend/Share (Rs.) | 32.00 | 28.00 | 22.00 | 48.00 | 35.00 |
| Face Value | 5 | 5 | 5 | 5 | 5 |
| Gross Profit Margin (%) | 32.51 | 31.93 | 30.01 | 30.88 | 31.69 |
| Operating Margin (%) | 25.61 | 24.39 | 22.66 | 23.10 | 23.47 |
| Net Profit Margin (%) | 16.59 | 15.44 | 12.94 | 9.13 | 15.63 |
| Return on Networth / Equity (%) | 25.17 | 24.15 | 20.09 | 13.05 | 21.44 |
| ROCE (%) | 28.71 | 27.16 | 22.79 | 22.63 | 20.46 |
| Return On Assets (%) | 12.75 | 10.99 | 8.29 | 5.93 | 8.89 |
| Current Ratio (X) | 1.19 | 1.03 | 0.98 | 1.20 | 1.13 |
| Quick Ratio (X) | 0.65 | 0.61 | 0.57 | 0.64 | 0.58 |
| Debt to Equity (x) | 0.40 | 0.57 | 0.85 | 0.67 | 0.83 |
| Interest Coverage Ratios (X) | 14.84 | 9.69 | 8.66 | 10.30 | 7.19 |
| Asset Turnover Ratio (%) | 0.77 | 0.71 | 0.68 | 0.53 | 0.50 |
| Inventory Turnover Ratio (X) | 4.70 | 0.74 | 0.63 | 0.68 | 0.70 |
| 3 Yr CAGR Sales (%) | 16.34 | 15.77 | 10.08 | 5.30 | 15.67 |
| 3 Yr CAGR Net Profit (%) | 56.82 | 15.03 | 10.24 | 33.46 | 35.87 |
| P/E (x) | 57.16 | 53.14 | 41.78 | 30.39 | 17.20 |
| P/B (x) | 14.42 | 12.84 | 8.40 | 7.95 | 7.37 |
| EV/EBITDA (x) | 29.89 | 26.60 | 19.66 | 19.38 | 18.62 |
| P/S (x) | 9.51 | 8.21 | 5.41 | 5.56 | 5.37 |
Torrent Pharmaceuticals announced a final dividend of Rs 6 per share (120%) with effective date as 20 Jun, 2025 and an interim dividend of Rs 26 per share (520%) with effective date as 31 Jan, 2025. The company had previously announced a bonus issue on May 25, 2022, with an ex-bonus date of July 8, 2022, in the ratio of 1:1. A stock split was announced on December 15, 2005, with an ex-split date of February 20, 2006, changing the face value from Rs 10 to Rs 5.
Moneycontrol analysis on September 19, 2025, indicated a very bullish sentiment for the stock.
Torrent Pharmaceuticals shares rose amid high trading volume, reflecting positive momentum coupled with recent corporate announcements and strong financial performance.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
